Journal of the American Academy of Dermatology
Volume 59, Issue 3 , Pages 385-396 , September 2008

Pediatric morphea (localized scleroderma): Review of 136 patients

,Accepted 7 May 2008.

References 

  1. Murray KJ, Laxer RM. Scleroderma in children and adolescents. Rheum Dis Clin North Am. 2002;28:603–624
  2. Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P, et al. Localized scleroderma in adults and children: clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003;13:171–176
  3. Bodemer C, Belon M, Hamel-Teillac D, Amoric JC, Fraitag S, Prieur AM, et al. Scleroderma in children: a retrospective study of 70 cases [French]. Ann Dermatol Venereol. 1999;126:691–694
  4. Pope JE. Scleroderma overlap syndromes. Curr Opin Rheumatol. 2002;14:704–710
  5. Krafchik BR. Localized morphea in children. Adv Exp Med Biol. 1999;455:49–54
  6. Vierra E, Cunningham BB. Morphea and localized scleroderma in children. Semin Cutan Med Surg. 1999;18:210–225
  7. Jablonska S, Blaszczyk M. Scleroderma overlap syndromes. Adv Exp Med Biol. 1999;455:85–92
  8. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma. Arthritis Rheum. 2004;50:227–232
  9. Uziel Y, Krafchik BR, Silverman ED, Thorner PS, Laxer RM. Localized scleroderma in childhood: a report of 30 cases. Semin Arthritis Rheum. 1994;23:328–340
  10. Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52:2873–2881
  11. Mayorquin FJ, McCurley TL, Levernier JE, Myers LK, Becker JA, Graham TP, et al. Progression of childhood linear scleroderma to fatal systemic sclerosis. J Rheumatol. 1994;21:1955–1957
  12. Birdi N, Laxer RM, Thorner P, Fritzler MJ, Silverman ED. Localized scleroderma progressing to systemic disease: case report and review of the literature. Arthritis Rheum. 1993;36:410–415
  13. Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998;39:211–215
  14. Hom C, Ilowite NT. Other rheumatic diseases in adolescence: dermatomyositis, scleroderma, overlap syndromes, systemic vasculitis, and panniculitis. Adolesc Med. 1998;9:69–83vi
  15. Isenberg DA, Black C. ABC of rheumatology: Raynaud's phenomenon, scleroderma, and overlap syndromes. BMJ. 1995;310:795–798
  16. Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA. Incidence of systemic sclerosis in Allegheny County, Pennsylvania: a twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum. 1997;40:441–445
  17. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children: an international study. Rheumatology (Oxford). 2006;45:614–620
  18. Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol. 1997;24:73–80
  19. Falanga V, Medsger TA, Reichlin M, Rodnan GP. Linear scleroderma: clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med. 1986;104:849–857
  20. Christianson HB, Dorsey CS, Kierland RR, O'Leary PA. Localized scleroderma; a clinical study of two hundred thirty-five cases. AMA Arch Derm. 1956;74:629–639
  21. Bastian HM, Alarcon GS, Roseman JM, McGwin G, Vila LM, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatology (Oxford). 2007;46:683–689
  22. Krishnan E, Hubert HB. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann Rheum Dis. 2006;65:1500–1505
  23. Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr. 2000;136:91–95
  24. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphea) in children. Br J Dermatol. 2006;155:1013–1020
  25. Fitch PG, Rettig P, Burnham JM, Finkel TH, Yan AC, Akin E, et al. Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol. 2006;33:609–614
  26. Mitchell H, Bolster MB, LeRoy EC. Scleroderma and related conditions. Med Clin North Am. 1997;81:129–149
  27. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81:139–153
  28. Jaffe MO, Winkelmann RK. Generalized scleroderma in children: acrosclerotic type. Arch Dermatol. 1961;83:402–413
  29. Goel KM, Shanks RA. Scleroderma in childhood: report of 5 cases. Arch Dis Child. 1974;49:861–866
  30. Bourgeois-Droin C, Touraine R. Scleroderma in plaques: immunological and visceral disturbances [French]. Ann Med Interne (Paris). 1978;129:107–112
  31. Tangsrud SE, Skyberg D, Larsen TE. Scleroderma with massive regional lymphadenopathy. Acta Paediatr Scand. 1979;68:627–628
  32. Person JR, Su WP. Subcutaneous morphea: a clinical study of sixteen cases. Br J Dermatol. 1979;100:371–380
  33. Torok E, Ablonczy E. Morphea in children. Clin Exp Dermatol. 1986;11:607–612
  34. Larregue M, Ziegler JE, Lauret P, Bonafe J, Lorette G, Titi A, et al. Linear scleroderma in children (apropos of 27 cases) [French]. Ann Dermatol Venereol. 1986;113:207–224
  35. Woo TY, Rasmussen JE. Juvenile linear scleroderma associated with serologic abnormalities. Arch Dermatol. 1985;121:1403–1405

 Funding sources: None.

 Conflicts of interest: None declared.

 Reprints not available from the authors.

PII: S0190-9622(08)00591-4

doi: 10.1016/j.jaad.2008.05.005

Journal of the American Academy of Dermatology
Volume 59, Issue 3 , Pages 385-396 , September 2008

Article Tools

* Image Usage & Resolution